Data from pre-clinical and clinical studies provide evidence that colony-stimulating factors (CSFs) and other growth factors (GFs) can improve stroke outcome by reducing stroke damage through their anti-apoptotic and anti-inflammatory effects, and by promoting angiogenesis and neurogenesis. This review provides a critical and up-to-date literature review on CSF use in stroke. We searched for experimental and clinical studies on haemopoietic GFs such as granulocyte CSF, erythropoietin, granulocyte-macrophage colony-stimulating factor, stem cell factor (SCF), vascular endothelial GF, stromal cell-derived factor-1α and SCF in ischemic stroke. We also considered studies on insulin-like growth factor-1 and neurotrophins. Despite promising results from animal models, the lack of data in human beings hampers efficacy assessments of GFs on stroke outcome. We provide a comprehensive and critical view of the present knowledge about GFs and stroke, and an overview of ongoing and future prospects.

Growth factors in ischemic stroke / S. Lanfranconi, F. Locatelli, S. Corti, L. Candelise, G. P. Comi, P. L. Baron, S. Strazzer, N. Bresolin, A. Bersano. - In: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. - ISSN 1582-1838. - 15:8(2011 Aug), pp. 1645-1687. [10.1111/j.1582-4934.2009.00987.x]

Growth factors in ischemic stroke

S. Lanfranconi
Primo
;
S. Corti;L. Candelise;G.P. Comi;N. Bresolin
Penultimo
;
A. Bersano
Ultimo
2011-08

Abstract

Data from pre-clinical and clinical studies provide evidence that colony-stimulating factors (CSFs) and other growth factors (GFs) can improve stroke outcome by reducing stroke damage through their anti-apoptotic and anti-inflammatory effects, and by promoting angiogenesis and neurogenesis. This review provides a critical and up-to-date literature review on CSF use in stroke. We searched for experimental and clinical studies on haemopoietic GFs such as granulocyte CSF, erythropoietin, granulocyte-macrophage colony-stimulating factor, stem cell factor (SCF), vascular endothelial GF, stromal cell-derived factor-1α and SCF in ischemic stroke. We also considered studies on insulin-like growth factor-1 and neurotrophins. Despite promising results from animal models, the lack of data in human beings hampers efficacy assessments of GFs on stroke outcome. We provide a comprehensive and critical view of the present knowledge about GFs and stroke, and an overview of ongoing and future prospects.
Rats ; Animals ; Granulocyte Colony-Stimulating Factor ; Granulocyte-Macrophage Colony-Stimulating Factor ; Humans ; Stroke ; Brain ; Brain Ischemia ; Mice ; Intercellular Signaling Peptides and Proteins
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Growth Factors and Ischaemic Stroke.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 666.23 kB
Formato Adobe PDF
666.23 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/204290
Citazioni
  • ???jsp.display-item.citation.pmc??? 35
  • Scopus 71
  • ???jsp.display-item.citation.isi??? 58
social impact